Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-α: relevance to hepatitis C

Free Radical Biology and Medicine

Volumn 47, Issue 1, 2009, Pages 47-54

  Joshi Barve, Swati ^a   Amancherla, Kiranmayi ^a   Patil, Madhuvanti ^a   Bhatnagar, Aruni ^a   Mathews, Stephanie ^a   Gobejishvili, Leila ^a   Cave, Matthew ^a,b   McClain, Craig ^a,b   Barve, Shirish ^a  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acrolein; Environmental pollutant; Free radicals; Hepatitis C virus; Interferon ; JAK STAT signaling; Lipid peroxidation products

Indexed keywords

ACROLEIN; ALPHA INTERFERON; LIPID HYDROPEROXIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; POLLUTANT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPLICON; VIRUS REPLICATION;

ACROLEIN; AIR POLLUTANTS; ANTIVIRAL AGENTS; CELLS, CULTURED; DOWN-REGULATION; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LIPID PEROXIDATION; POLYETHYLENE GLYCOLS; REPLICON; SIGNAL TRANSDUCTION; SMOKING; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VIRULENCE; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 67349122722     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.03.021     Document Type: Article

References (46)

1. World Health Organization Fact Sheet No. 164, Geneva: WHO; 2000.
2. Chou R., Clark E.C., and Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 140 (2004) 465-479
3. Davis G.L., Albright J.E., Cook S.F., and Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 9 (2003) 331-338
4. Benvegnu L., Gios M., Boccato S., and Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53 (2004) 744-749
5. Ikeda K., Saitoh S., Suzuki Y., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J. Hepatol. 28 (1998) 930-938
6. Ferenci P. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol. Dietol. 52 (2006) 157-174
7. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132 (2000) 296-305
8. Fried M.W., Shiffman M.L., Reddy R., Smith C., Marino G., Goncales F., et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C. N. Engl. J. Med. 347 (2002) 975-982
9. Schindler C., Levy D.E., and Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282 (2007) 20059-20063
10. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
11. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
12. Takaoka A., and Yanai H. Interferon signaling network in innate defence. Cell Microbiol. 8 (2006) 907-922
13. E l-Zayadi A., Selim O., Hamdy H., El-Tawil A., Hanaa M., et al. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J. Gastroenterol. 10 (2004) 2963-2966
14. Mahmood S., Kawanaka M., Kamei A., Izumi A., Nakata K., Niiyama G., et al. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid. Redox Signaling 6 (2004) 19-24
15. Konishi M., Iwasa M., Araki J., Kobayashi Y., Katsuki A., Sumida Y., et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J. Gastroenterol. Hepatol. 21 (2006) 1821-1825
16. Naoki F., Shinichiro H., Ryosuke S., Hideaki T., et al. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic. Biol. Med. 42 (2007) 353-362
17. Paradis V., Mathurin P., Kollinger M., Imbert-Bismut F., Charlotte F., Piton A., et al. In situ detection of lipid peroxidation of chronic hepatitis C: correlation with pathological features. J. Clin. Pathol. 50 (1997) 401-406
18. Larrea E., Beloqui O., Munoz-Navas M.A., Civeira M.P., and Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic. Biol. Med. 24 (1998) 1235-1241
19. Barbaro G., Di Lorenzo G., Ribersani M., Soldini M., Giancaspro G., Bellomo G., et al. Serum and hepatic glutathione concentrations in chronic hepatitis C patients related to hepatitis C virus genotype. J. Hepatol. 30 (1999) 774-782
20. Di Bona D., Cippitelli M., Fionda C., Camma C., Licata A., Santoni A., and Craxi A. Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. J. Hepatol. 45 (2006) 271-279
21. Stevens J.F., and Maier C.S. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol. Nutr. Food Res. 52 (2008) 7-25
22. Environmental Protection Agency. Toxicological profile for acrolein (2007), U.S. Department of Health and Human Services Agency for Toxic Substances and Disease Registry, Atlanta
23. Lambert C., McCue J., Portas M., Ouyang Y., Li J., Rosano T.G., et al. Acrolein in cigarette smoke inhibits T-cell responses. J. Allergy Clin. Immunol. 116 (2005) 916-922
24. Kehrer J.P., and Biswal S.S. The molecular effects of acrolein. Toxicol. Sci. 57 (2000) 6-15
25. Biswal S., Acquaah-Mensah G., Datta K., Wu X., and Kehrer J.P. Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications. Chem. Res. Toxicol. 15 (2002) 180-186
26. Ranganna K., Yousefipour Z., Nasif R., Yatsu F.M., Milton S.G., and Hayes B.E. Acrolein activates mitogen-activated protein kinase signal transduction pathways in rat vascular smooth muscle cells. Mol. Cell. Biochem. 240 (2002) 83-98
27. Luo J., and Shi R. Acrolein induces axolemmal disruption, oxidative stress and mitochondrial impairment in spinal cord tissue. Neurochem. Int. 44 (2004) 475-486
28. Yang X., Wu X., Choi Y.E., Kern J.C., and Kehrer J.P. Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology 204 (2004) 209-218
29. Calingasan N.Y., Uchida K., and Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 72 (1999) 751-756
30. Mercado C., and Jaimes E.A. Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights. Curr. Hypertens. Rep. 9 (2007) 66-72
31. Daimon M., Sugiyama K., Kameda W., Saitoh T., Oizumi T., Hirata A., et al. Increased urinary levels of pentosidine, pyrraline and acrolein adduct in type 2 diabetes. Endocr. J. 50 (2003) 61-67
32. Joshi-Barve S., Barve S.S., Butt W., Klein J., and McClain C.J. Inhibition of proteasome function leads to NF-κB-independent IL-8 expression in human hepatocytes. Hepatology 38 (2003) 1178-1187
33. De Francesco R., and Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 436 (2005) 953-960
34. Lovell M.A., Xie C., and Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 22 (2001) 187-194
35. Park Y.S., and Taniguchi N. Acrolein induces inflammatory response underlying endothelial dysfunction: a risk factor for atherosclerosis. Ann. N. Y. Acad. Sci. 1126 (2008) 185-189
36. Park Y.S., Kim J., Misonou Y., Takamiya R., Takahashi M., Freeman M.R., and Taniguchi N. Acrolein induces cyclooxygenase-2 and prostaglandin production in human umbilical vein endothelial cells: roles of p38 MAP kinase. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1319-1325
37. Mahmood S., Yamada G., Niiyama G., Kawanaka M., Togawa K., Sho M., Ito T., Sasagawa T., Okita M., Nakamura H., and Yodoi J. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic. Res. 37 (2003) 781-785
38. El-Zayadi A.R. Heavy smoking and liver. World J. Gastroenterol. 12 (2006) 6098-6101
39. Pessione F., Ramond M.J., Njapoum C., Duchatelle V., Degott C., Erlinger S., et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 34 (2001) 121-125
40. Fujita Y., Shibata A., Ogimoto I., Kurozawa Y., Nose T., Yoshimura T., et al. The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br. J. Cancer 94 (2006) 737-739
41. Dev A., Patel K., Conrad A., Blatt L.M., and McHutchison J.G. Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 4 (2006) 797-801
42. Hezode C., Lonjon I., Roudot-Thoraval F., Mavier J.P., Pawlotsky J.M., Zafrani E.S., et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 52 (2003) 126-129
43. Wang C.S., Wang S.T., Chang T.T., Yao W.J., and Chou P. Smoking and alanine aminotransferase levels in hepatitis C virus infection: implications for prevention of hepatitis C virus progression. Arch. Intern. Med. 162 (2002) 811-815
44. Caramella S.G., Chen M., Zhang Y., Zhang S., Hatsukami D.K., and Hecht S.S. Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking. Chem. Res. Toxicol. 20 (2007) 986-990
45. Liu W., Akhand A.A., Takeda K., Kawamoto Y., Itoigawa M., et al. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ. 10 (2003) 772-781
46. Seiner D.R., Labutti J.N., and Gates K.S. Kinetics and mechanism of protein tyrosine phosphatase 1B inactivation by acrolein. Chem. Res. Toxicol. 20 (2007) 1315-1320